Monitoring Immune Toxicities in Squamous NSCLC

In this segment, the panel discusses the importance of proactive monitoring and multidisciplinary management of immune-related toxicities in patients with advanced squamous non-small cell lung cancer (NSCLC). Dr. Edward Kim emphasizes regular laboratory monitoring and maintaining a high level of clinical suspicion because immune-related adverse events can present with nonspecific symptoms and may occur unpredictably, including well after treatment initiation. Dr. Narjust Florez highlights how clinicians have become more familiar with recognizing and managing toxicities over time and stresses the importance of educating community physicians, nurses, and advanced practice providers. Dr. Christian Rolfo describes the development of dedicated immune toxicity clinics that bring together specialists such as rheumatologists, dermatologists, and pulmonologists to facilitate rapid evaluation and management. The panel also emphasizes the need to educate emergency departments and other care settings about appropriate management of immune-related adverse events. Looking ahead, the experts discuss the need to prepare for distinct toxicity profiles associated with antibody-drug conjugates and emerging cell therapies.